Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086558 | 1.00 | KMT2A (0.65) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5080649 | 0.90 | KMT2A (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083215 | 0.84 | DPP4 (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083144 | 0.84 | DPP4 (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5080362 | 0.84 | DPP4 (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083223 | 0.84 | DPP4 (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083140 | 0.84 | DPP4 (0.52) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083242 | 0.84 | EPHA2 (0.49) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5083883 | 0.84 | LMNA (0.65) | KMT2AEPHA2FLT4GSK3BRARB | |
| SCHEMBL5084072 | 0.84 | LMNA (0.53) | KMT2AEPHA2FLT4GSK3BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-5385906-A | Treating gramnegative and grampositive bacterial infections | THE UPJOHN COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| US-5262417-A | Antibacterial quinolone compounds | THE UPJOHN COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| EP-0447484-A1 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-25 | — | — | EP | disclosed |
| WO-1990006307-A2 | ANTIBACTERIAL QUINOLONE COMPOUNDS | THE UPJOHN COMPANY (US) | 1990-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KMT2A 1354/4885EPHA2 2318/4885FLT4 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.